BioSpace News Archive

Evaxion Biotech A/S, a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, presented promising clinical data from its EVX-01 Phase 1 dose escalation trial in metastatic melanoma at the 2023 ASCO annual meeting in Chicago, Illinois.

Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, announced positive interim clinical data from the ongoing Phase 1 study of its lead asset, ELI-002, an investigational therapeutic cancer immunotherapy.

Blueprint Medicines Corporation announced clinical data for multiple programs across its precision therapy portfolio at the 2023 American Society of Clinical Oncology Annual Meeting.

Precigen, Inc. presented positive clinical data from the Phase 1 study of the off-the-shelf PRGN-2009 AdenoVerse™ immunotherapy alone and in combination with an investigational anti-PDL1/TGF-Beta Trap checkpoint inhibitor in patients with recurrent/metastatic HPV-associated cancers at the 2023 American Society of Clinical Oncology Annual Meeting.

Replimune Group, Inc. announced updated data from the first 75 patients in the anti-PD1 failed melanoma cohort of the IGNYTE clinical trial along with data from the ongoing Phase 1 trial of RP2 combined with nivolumab in patients with uveal melanoma are being presented at the ASCO annual meeting.

Innovent Biologics, Inc. updated the Phase 1b efficacy and safety results of IBI939 combined with sintilimab in previously untreated PD-L1-selected NSCLC without sensitizing mutations at the 2023 American Society of Clinical Oncology Annual Meeting.

Affimed N.V. announced the presentation at the American Society of Clinical Oncology Annual Meeting of safety and efficacy data from the EGFR mutant NSCLC expansion cohort of its ongoing phase 1/2 study investigating innate cell engager AFM24 as monotherapy.

Gilead Sciences, Inc. and Arcus Biosciences, Inc. announced updated results from an interim analysis of the ARC-7 study in patients with first-line, metastatic non-small cell lung cancer with PD-L1 tumor proportion score ≥50% without epidermal growth factor receptor or anaplastic lymphoma kinase mutations.

GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, announced data evaluating the Galleri® multi-cancer early detection test’s ability to detect a cancer signal and predict the cancer signal origin in asymptomatic individuals in the real-world setting.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated results from the pivotal Phase 1/2 MonumenTAL-1 study of the investigational bispecific antibody talquetamab in the treatment of patients with relapsed or refractory multiple myeloma.